IVVD Profile
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Established in 2020 and headquartered in Waltham, Massachusetts, the company aims to address significant unmet medical needs by developing innovative therapies. Its lead product candidate, adintrevimab, is a neutralizing antibody currently in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. This promising candidate is designed to offer broad and durable protection against multiple variants of the virus.
In addition to its work on coronavirus, Invivyd, Inc. is actively advancing its pipeline with discovery-stage candidates targeting the prevention of seasonal influenza. These efforts reflect the company's broader strategy to combat infectious diseases through potent antibody-based therapeutics. By leveraging its expertise in antibody discovery and development, Invivyd aims to create effective treatments that can be rapidly deployed in response to emerging infectious threats.
Invivyd, Inc. has established strategic collaborations to enhance its research and development capabilities. The company has a collaboration agreement with Adimab, LLC, which focuses on the discovery and optimization of proprietary antibodies. Additionally, Invivyd partners with the Scripps Research Institute to identify vaccine candidates for the prevention, diagnosis, or treatment of influenza and beta coronaviruses. These partnerships are integral to Invivyd's approach to innovation and its mission to deliver transformative therapies.
Formerly known as Adagio Therapeutics, Inc., Invivyd, Inc. rebranded in September 2022 to better reflect its expanded focus and commitment to addressing global health challenges. Through its cutting-edge research, robust pipeline, and strategic partnerships, Invivyd is poised to make a significant impact in the field of infectious disease therapeutics, offering hope and improved health outcomes to patients worldwide.
|
